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Background: Very low calorie diet (VLCD) is routinely used in programs for treatment of obesity and before
bariatric surgery in order to reduce risk of postoperative complications. Aspartame, an artificial sweetener, is
commonly used in VLCD and is well approved as a food additive without any adverse effects. The development of a
new fructose containing VLCD formula without aspartame raises questions as to effects on glucose and lipid control.
Methods: As part of an ongoing study of a novel bariatric surgery procedure, twenty-five obese subjects with mean
body mass index (BMI) 39.8 kg/m2 and mean age of 48.8 years enrolled in a single center observational study. Seven
subjects presented with type 2 diabetes mellitus. The subjects underwent four weeks dietary treatment with VLCD
Slanka (Slanka®). Blood samples including fasting plasma glucose, HbA1c, cholesterol and triglycerides were performed
at start and after four weeks of diet. Blood pressure and weight were noted.
Results: All subjects completed the diet without any adverse events. Mean weight reduction was 8.2 kg with 95%
confidence interval 7.1–9.2 kg (p = 0.001). Excess weight (i.e. proportion of weight exceeding BMI 25) loss
decreased by median 19.5% (inter quartile range (IQR) 16,8-24,2). Median fasting plasma glucose was at inclusion
5,6 mmol/l (IQR 5,3-6,8) and after diet 4.8 mmol/l (IQR 4,6-5,2) (p = 0.001). Median HbA1c changed from 39
mmol/mol (IQR 37–44) to 37 mmol/mol (IQR 35–43) (p = 0.001). There was also significant reduction in
cholesterol and triglyceride levels as well as in systolic blood pressure. Changes in other monitored blood
chemistry values were without clinical importance.
Conclusion: Four weeks treatment with fructose containing VLCD of obese subjects preparing for bariatric
surgery gave a substantial weight reduction without any significant negative metabolic effects.
Keywords: Obesity, VLCD, Fructose, Aspartame, Artificial sweetener, Weight reductionBackground
Adult obesity is defined by WHO as body mass index
(BMI) greater than 30 kg/m2. Prevalence of obesity has
been increasing worldwide over the last few decades.
Obesity prevalence in the United States was 35.5%
among men and 35.8% among women in 2009–2010,
with no significant change compared to 2003–2008 [1].
In young and middle aged men and women all-cause
mortality risk appear to be directly related to increase in
BMI [2]. Bariatric surgery for severe obesity is associated* Correspondence: erik.noren@ltblekinge.se
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article, unless otherwise stated.with long-term weight loss and decreased overall mortality
[3], in both sexes [4].
Very low calorie diet (VLCD) contains less than 800
kcal per day. VLCD are routinely being used prior to
bariatric surgery. Such practice reduces liver volume [5],
reduces postoperative complication rates and reduces
the perceived technical difficulty of the procedure [6].
Aspartame, an artificial sweetener, is commonly used
in VLCD and is well approved as a food additive without
any adverse effects [7]. This has also been proven for
heterozygotes for phenylketonuria (PKU) [8]. The devel-
opment of a new VLCD formula (Slanka®) with fructose
instead of aspartame raises questions as to effects on
glucose and lipid control.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 2 Coexisting conditions in enrolled 25 subjects
Condition under treatment Number of subjects
Type 2 diabetes mellitus (total) 7
- Dietary treatment 2
- Metformin 4




- Beta receptor antagonist 3
Hyperlipidemia (total) 4
- Statin 4
Mood disorder (total) 7
- SSRI 7
Table 3 Slanka contents per portion and daily intake
Per portion 45 g Daily intake 180 g
Energy kcal/kJ 170/700 680/2800
Proteins g 17 68
Carbohydrate g
(including Fructose g)
17 (3,5-5) 68 (14–20)
Fat g 4 16
Fibers g 1 4
Vitamin A mg 0.4 1.6
Vitamin D μg 1.8 7.2
Vitamin E mg 3.6 14.4
Vitamin K μg 23 92
Tiamine mg 0.6 2.4
Riboflavine mg 0.9 3.6
Niacine mg 6,2 24.8
Vitamin B6 μg 0.8 3.2
Vitamin B12 μg 1,5 6.0
Folacine μg 76 304
Vitamin C mg 23 92
Sodium g 0.4 1.6
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is 37 g per 100 g. The daily amount of formula consumed
during diet is approximately 180 g of which fructose is
approximately 20 g. According to a review of health im-
plications of fructose consumption [9], moderate fruc-
tose consumption of less than 50 g/day probably does
not have any deleterious effect on lipid and glucose con-
trol. It is also known that diet rich in carbohydrates may
have an increased risk of metabolic side effects [10].
The aim of this observational study is to investigate
the effects of fructose containing VLCD in obese sub-
jects, prior to bariatric intervention, on selected meta-
bolic variables.
Methods
As part of our ongoing single-center prospective study
of a novel bariatric surgery procedure (Forssell H, Norén E,
Six Month Results with Aspire Assist® - a Novel Endoscopic
Weight Loss Therapy, submitted manuscript), twenty-five
obese subjects consecutive enrolled after consent from the
Regional Ethical Review Board in Lund, Sweden.
Baseline demographics are presented in Table 1. In
summary there were 23 women and 2 men with mean
BMI 39.8 kg/m2 and mean age 48.8 years. Seven subjects
presented with type 2 diabetes mellitus (T2DM), four
were treated with metformin, one with insulin and two
had only dietary treatment. Other significant coexisting
conditions are depicted in Table 2.
The subjects underwent four weeks dietary treatment
with VLCD Slanka®, Table 3, (Slanka Sverige AB, Sweden)
corresponding to approximately 680 kcal per day
(four portions). Slanka contains milk proteins and
approximately 25 g lactose per 100 g formula. The
main sweetener is sugar beet fructose and secondary
Acesulfame K, an artificial sweetener that is excreted
unchanged in urine. Slanka contains rapeseed oil fat
(information from Slanka Sverige AB, Sweden).
Blood samples were analyzed for HbA1c, fasting plasma
glucose (FPG), cholesterol and triglycerides. Measurements
were done at inclusion and after four weeks of diet. Change
in blood pressure and weight was noted. Blood samples
were also analyzed for electrolytes, blood cells, CRP and
liver enzymes, see Table 3.
Statistical analysis was performed with Stata version
13.1. Skewness/Kurtosis test was used for assessmentTable 1 Baseline demographics
Mean Standard error Range (min-max)
Age (years) 48.8 1.66 33-65
BMI (kg/m2) 39.8 0.9 35.1-49
Weight (kg) 107.4 3.7 85.8-148
Excess weight (kg) 40.2 2.8 24.8-68.6
Baseline demographics at inclusion. Excess weight is weight exceeding BMI 25.of distribution of data (parametric or non-parametric).
Students t-test and Wilcoxon signed-rank test were
used for parametric and non-parametric analysis of dif-
ferences, respectively. P-value <0.05 was considered
statistically significant.Potassium g 0.7 2.8
Calcium g 0.4 1.6
Chloride g 0.6 2.4
Phosphor mg 400 1600
Magnesium mg 140 560
Iron mg 5.5 22.0
Zink mg 4.8 19.2
Figure 1 Change in body weight with VLCD. Mean weight (95% confidence interval), kg, before and after 4 weeks dietary treatment with
fructose containing VLCD.
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After four weeks of fructose containing VLCD all 25
subjects had mean weight loss of 8.2 kg as presented in
Figure 1. Median excess weight (exceeding BMI 25) loss was
19.5% (inter quartile range 16.8-24.2). Changes in weight,
blood pressure, lipids and FPG are presented in Table 4.
All variables except diastolic blood pressure (DBP) were
significantly reduced. DBP was significantly increased. ItTable 4 Changes in metabolic variables; weight, blood
pressure, glucose and lipids
All subjects
Variable Inclusion After diet,
four weeks
P N
Weight (kg)* 107.4 (99.6-115.1) 99.3 (92.1-106.4) 0.001 25
BMI (kg/m2)* 39.8 (38.0-41.6) 36.8 (35.1-38.6) 0.001 25
Excess weight* 40.2 (34.5-45.9) 32.1 (26.8-37.4) 0.001 25
SBP (mmHg)§ 150 (140–150) 135 (125–140) 0.005 25
DBP (mmHg)§ 85 (80–90) 90 (85–95) 0.04 25
Glucose (mmol/l)§ 5.6 (5.3-6.8) 4.8 (4.6-5.2) 0.001 24
HbA1c (mmol/mol)
§ 39 (37–44) 37 (35–43) 0.001 23
Cholesterol (mmol/l)§ 5.4 (4.9-6.2) 4.4 (4.1-4.9) 0.001 22
Triglycerides (mmol/l)§ 1.6 (1.1-2.2) 1.2 (1.1-1.6) 0.006 21
Subjects with type 2 diabetes mellitus
Variable Inclusion After diet,
four weeks
P N
Weight (kg)* 119.2 (99.3-139.1) 110.3 (91.5-129.1) 0.02 7
Glucose (mmol/l)§ 7.5 (7.0-12.5) 6.0 (4.8-6.8 0.02 7
HbA1c (mmol/mol)
§ 47 (44–66) 46 (45–59) 0.11 7
SBP = Systolic blood pressure. DBP = Diastolic blood pressure. *Presented as
mean (95% confidence interval). §Presented as median (inter quartile range).
P-value denotes the level of statistical significance in the difference between
value at inclusion and after diet.is noteworthy that at inclusion 15 subjects had elevated
SBP (above 140 mm Hg). After diet 10 of these were im-
proved but 5 subjects still had elevated SBP.
Five of the seven subjects with T2DM had FPG above
7.0 mmol/l at inclusion. One subject without known T2DM
also presented with FPG above 7.0 mmol/l. Three sub-
jects with T2DM presented with HbA1c levels above 52
mmol/mol at inclusion, indicating insufficient treatment
T2DM control. One of these improved during treatment
with VLCD, and reached normal level of HbA1c. The
only subject who persisted with FPG above 7.0 mmol/l
after four weeks of diet was the patient with the highest
FPG at inclusion, who also had a persisting elevated
HbA1c value. Change in FPG and HbA1c levels are pre-
sented in Figure 2 and Figure 3, respectively. Change in
weight, FPG and HbA1c levels for the diabetic subjects are
also presented separately in Table 4.
Triglyceride levels above 1.7 mmol/l were present in
11 subjects at inclusion, and improved in 6 of these after
treatment. Similar results were found regarding cholesterol.
Seventeen subjects had cholesterol above 5.0 mmol/l at in-
clusion and 12 improved after dietary treatment.
Blood chemistry of electrolytes and blood cell count are
displayed in Table 5. There were only minor or no changes
indicating no clinically significant adverse effects of
the diet. Liver enzymes AST and ALT were signifi-
cantly increased, but still well within normal range and
the changes were minor.
Discussion
Four weeks of the fructose containing VLCD Slanka
led to improved metabolic control. Overweight was
reduced with almost 20%. FPG, HbA1c, triglycerides and
cholesterol levels were significantly reduced. Blood pressure
was improved.
Figure 2 Change in fasting glucose with VLCD. Median fasting plasma glucose level (inter quartile range), mmol/l, before and after 4 weeks
dietary treatment with fructose containing VLCD.
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that isocaloric exchange of fructose for other carbohy-
drates does not induce non-alcoholic fatty liver disease
in otherwise healthy individuals. Diets containing high
doses of fructose (more than 100 g per day) may induce
changes associated with non-alcoholic fatty liver disease
[11]. The small changes in liver enzymes, well within
normal range, in the context of a small dose of fructose
(20 g per day) leads to the conclusion that this change is
not a cause for concern during a 4 week treatment.
Although our results clearly indicate improved metabolic
control we can draw no certain conclusion as to how the
fructose component affected the metabolism. Our study
lack a control group and we therefore have to compare
with previously published results, summarized in Table 6.
An earlier Swedish trial [12] by Wikstrand et al. in-
vestigating an adjunctive 9 months abdominal corsetFigure 3 Change in HbA1c with VLCD. Median HbA1c level (inter quartile
fructose containing VLCD.(ie an circumferential abdominal restrain device) treatment
versus control after 3 months of VLCD in obese subjects
has shown similar results of the dietary treatment as
we find in our study. The VLCD (Nutrilett, Cederroth
International AB) contains fructose, Acesulfame K and
aspartame. The subjects in this study were of same
population and age as ours, but had somewhat less
overweight. It is interesting to note that the metabolic
improvement partially persists 9 months after the diet
was finished and is similar to that which we saw imme-
diately after 4 weeks of diet in our study.
Case et al. [13] reports a similar reduction of FGP in
an observational consecutive VLCD program in the US
including 125 subjects with metabolic syndrome. The
VLCD (Nutrimed-Plus, Robard Corporation, Mount
Laurel, NJ, USA) used in the study contains approximately
600–800 kcal per day and 30–40 g carbohydrate perrange), mmol/mol, before and after 4 weeks dietary treatment with
Table 5 Laboratory variables
Variable Inclusion After diet,
four weeks
P N
CRP (mg/l)* 5.0 (4.9-8.0) <5 0.04 25
Hemoglobin (g/l) 135 (132–140) 138 (132.5-143.5) 0.01 24
Trombocytes (109/l) 325 (244–389) 316 (203–357) 0.01 24
White blood cells (109/l) 6.5 (5.9-7.8) 6.8 (5.95-7.6) 0.71 24
Mean cellular volume (fl) 88 (86–91) 88 (85.5-90.5) 0.12 24
Sodium (mmol/l) 140 (139–141) 139 (139–141) 0.91 25
Potassium (mmol/l) 4.3 (4.1-4.5) 4.3 (4.1-4.4) 0.04 21
Calcium (mmol/l) 2.37 (2.32-2.41) 2.42 (2.36-2.47) 0.06 25
Creatinine (μmol/l) 61 (53–67) 76 (53–75) 0.19 23
Bilirubin (μmol/l) 8 (7–10) 9 (8–12) 0.03 25
ALT (μkat/l) 0.48 (0.37-0.64) 0.53 (0.39-0.98) 0.01 25
AST (μkat/l) 0.35 (0.30-0.44) 0.42 (0.34-0.62) 0.001 24
ALP (μkat/l) 1.36 (1.11-1.48) 1.26 (0.91-1.39) 0.02 25
Changes in non-metabolic blood chemistry values. Presented as median
(inter quartile range). P-value denotes the level of statistical significance in the
difference between value at inclusion and after diet. *Low-sensitive CRP.
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carbohydrate per day.
Gu et al. performed an observational study [14] in a
Chinese population including 53 overweight or obese
(BMI > 28) but otherwise healthy subjects. The subjects
consumed VLCD with less than 800 kcal per day and
less than 20 g carbohydrate per day for 8 weeks. As seen in
Table 6 our diet with a higher amount of carbohydrate led
to a more favorable change in FGP level despite shorter
treatment and presence of significant comorbidities. The
difference between studies can partially be explained
by the absence of T2DM – and thus normal FGPD at
inclusion – in the Chinese group.Table 6 Literature review of demographics and FPG
Study N (♀/♂) Age BMI FPG at inclusion
Present study 25 (23/2) 48.8 (1,66)‡ 39.8 (0.9)‡ 5.6 (5.3-6.8)#
Case 125 (?/?) 48.4 (10.4)* 40.7 (9.7)* 6.4 (2.1)*
Wikstrand [12] 46 (?/?) 46 (9)* 35.4 (3,4)* 5.2 (0.9)*
- Group A
Wikstrand [12] 48 (?/?) 48 (9)* 36.1 (3.7)* 5.3 (2.2)*
- Group B
Yunjuan [14] 53 (?/?) ? 32.6 (0.6)‡ 5.3 (0.1)‡
Jackness [15] 11 (7/4) 44.6 (3.0)‡ 43.2 (2.3)‡ 9.9 (1.2)‡
- RYGP
Jackness [15] 14 (8/6) 51.9 (2.0)‡ 39.2 (1.0)‡ 10.2 (0.7)‡
- VLCD
Literature review demographics and FPG in different studies. Search was performed
“aspartame” or “fructose” as search text. The review was arbitrarily limited to article
full-text publications. Abstracts were reviewed in order to find results related to the
glucose was treated equal to fasting plasma glucose [11]. All studies except Jackne
received similar VLCD-regime. *Presented as mean (standard deviation). ‡PresentedJackness et al. [15] compared two groups of obese subjects
with T2DM in the US. One group underwent bariatric sur-
gery with Roux-en-Y gastric bypass (RYGBP) and the other
had VLCD for three weeks. Both groups had high levels of
HbA1c at inclusion (mean 66 and 69 mmol/mol respectively).
Insulin sensitivity, β-cell function and glucose tolerance
were measured. The authors conclude that the early
beneficial effects after RYGP probably are caused by cal-
oric restriction. Results are strengthened by the Netherlands
study of Lips et al. [16]. Our study group contains mainly
subjects without T2DM. HbA1c at inclusion was median 39
mmol/mol. Therefore, as expected, the reduction in FPG is
not as explicit in our results.
It has been shown that obese subjects with T2DM started
on VLCD, in whom all glucose lowering medication has
been discontinued, some subjects respond with reduction
of FPG almost immediately, while others did not respond
at all. This change in FPG is probably dependent on the
capacity of β-cells to secrete insulin, and is independent
of weight change [17]. The same research group has also
shown that the positive metabolic effects of 30 day VLCD
leads to a sustained improvement in metabolic control up
to 18 months follow-up [18].
Although VLCD and other calorie restricted diets have
been widely used for many years, there is still scarce of
large randomized clinical trials. The effectiveness of a diet
is often improved by combination with physical exercise
and behavioral interventions [19]. In summary, there is
little evidence available to support the extended use of
VLCD for weight reduction in obese adults. Little is
known of long-term health outcome and quality of life
[20]. This is in contrast to the long-term effects of bar-
iatric surgery, which has been studied in detail with
known positive effects [3].FPG after diet Country Comments
4.8 (4.6-5.2)# Sweden 2013 7 subjects with T2DM. 4 weeks diet.
5.4 (1.2)* U.S. 2002 Metabolic syndrome. 4 weeks diet.
4.8 (0.5)* Sweden 2010 Prevalence of T2DM unknown.
12 weeks diet.
4.7 (0.6)*
5.2 (0.1)‡ China 2013 Healthy, no T2DM. 8 weeks diet.
6.9 (1.2)‡ U.S. 2013 All T2DM. 3 weeks diet.
6.1 (0.3)‡
using www.pubmed.gov with “VLCD” in combination with either “glucose”,
s published the last 20 years, between 1993 and 2013 and only to include
aim of this study; primary outcome FPG levels after VLCD. Fasting serum
ss et al. are observational regarding VLCD. Both groups in Wikstrand et al.
as mean (standard error). #Presented as median (inter quartile range).
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fects resulting from the replacement of aspartame with
fructose. Our results with fructose containing VLCD
seem to be equivalent to earlier published results from
VLCD with artificial sweetener in short-term outcome.
The addition of fructose seems to be of lesser import-
ance than severity of hyperglycemia at start of diet.
Although there is no strong evidence against use of
artificial sweeteners as food additives there are still
subjects whom out of personal believe wish to avoid
consuming artificial additives. In obese patients pre-
paring for bariatric surgery with VLCD there seems to
be no negative metabolic effects regarding blood sam-
ples and laboratory analysis measured in this study.
Based on this limited observational study we do not
find any contraindications for VLCD with fructose in-
stead of artificial sweetener before bariatric surgery.
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